ClinicalTrials.gg

Program

KAT2A/B Inhibitor PF-07994525

In Pfizer’s pipeline, KAT2A/B catalytic inhibitor. Its studies are led by Pfizer.

Furthest: phase 1, since Feb 16, 20261 company-led study, 1 open or runningNext primary completion: Jul 10, 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer11 open or runningphase 1since Feb 16, 2026Feb 16, 2026Jul 10, 2029phase 1 · NCT07426757
  • Named in Pfizer’s own pipeline as PF-07994525, phase 1, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 16, 2026First study: phase 1 study in Advanced MalignanciesFirst studyNCT07426757 · 120 planned · United States, Canada

Ahead

  1. Jul 10, 2029Primary completion: phase 1 study in Advanced MalignanciesNCT07426757

TargetBeta

“KAT2A/B catalytic inhibitor”the company's pipeline, read by Claude · source
“An orally bioavailable, small molecule inhibitor of the histone acetyltransferases and transcriptional activators lysine acetyltransferase 2A (KAT2A) and its paralog lysine acetyltransferase 2B (KAT2B), with potential antineoplastic activity. Upon oral administration, KAT2A/B inhibitor PF-0799452…”NCIt, read by Claude
“An orally bioavailable, small molecule inhibitor of the histone acetyltransferases and transcriptional activators lysine acetyltransferase 2A (KAT2A) and its paralog lysine acetyltransferase 2B (KAT2B), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
KAT2A/KAT2B Degrader AUTX-703ruleauron-therapeutics-incphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07426757Advanced Malignancies · United States, Canada1RecruitingJul 10, 2029120

How it is read

Names in the registry

  • “PF-07994525”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.